Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A

Fager Ferrari, Marcus LU orcid ; Roslund, Josefin LU ; Manderstedt, Eric LU ; Berntorp, Erik LU and Astermark, Jan LU (2026) In European Journal of Haematology
Abstract
Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success. Data were accrued from 237 patients with severe HA (FVIII level < 1%), history of persistent FVIII inhibitors ≥ 1 BU/mL and having performed ITI. Constitutional and clinical variables associated with ITI outcome were evaluated and multivariable logistic regression models developed. The F8 variant, age at inhibitor detection, and historical peak inhibitor titer were associated with ITI outcome. HLA DRB1*1501 and DQB1*0602 were linked to each other, but not associated with ITI outcome.... (More)
Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success. Data were accrued from 237 patients with severe HA (FVIII level < 1%), history of persistent FVIII inhibitors ≥ 1 BU/mL and having performed ITI. Constitutional and clinical variables associated with ITI outcome were evaluated and multivariable logistic regression models developed. The F8 variant, age at inhibitor detection, and historical peak inhibitor titer were associated with ITI outcome. HLA DRB1*1501 and DQB1*0602 were linked to each other, but not associated with ITI outcome. In a multivariable-adjusted model, large gene deletions, peak titer ≥ 25 BU/mL, and higher age at inhibitor detection were associated with a significantly lower ITI success rate. The discriminatory power of a predictive model was 0.87 (95% confidence interval [CI], 0.85–0.93) with the historical peak titer and 0.69 (95% CI, 0.64–0.80) without. We conclude that the peak inhibitor titer is a key determinant for ITI outcome and additional constitutional markers need to be defined for useful prediction in the clinical setting. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
European Journal of Haematology
article number
ejh.70269
publisher
Wiley-Blackwell
external identifiers
  • pmid:42492911
ISSN
1600-0609
DOI
10.1111/ejh.70269
language
English
LU publication?
yes
id
e4cd4621-680b-42b6-9ff3-e3f13dbe8019
date added to LUP
2026-07-25 14:40:10
date last changed
2026-07-27 09:25:09
@article{e4cd4621-680b-42b6-9ff3-e3f13dbe8019,
  abstract     = {{Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success. Data were accrued from 237 patients with severe HA (FVIII level &lt; 1%), history of persistent FVIII inhibitors ≥ 1 BU/mL and having performed ITI. Constitutional and clinical variables associated with ITI outcome were evaluated and multivariable logistic regression models developed. The F8 variant, age at inhibitor detection, and historical peak inhibitor titer were associated with ITI outcome. HLA DRB1*1501 and DQB1*0602 were linked to each other, but not associated with ITI outcome. In a multivariable-adjusted model, large gene deletions, peak titer ≥ 25 BU/mL, and higher age at inhibitor detection were associated with a significantly lower ITI success rate. The discriminatory power of a predictive model was 0.87 (95% confidence interval [CI], 0.85–0.93) with the historical peak titer and 0.69 (95% CI, 0.64–0.80) without. We conclude that the peak inhibitor titer is a key determinant for ITI outcome and additional constitutional markers need to be defined for useful prediction in the clinical setting.}},
  author       = {{Fager Ferrari, Marcus and Roslund, Josefin and Manderstedt, Eric and Berntorp, Erik and Astermark, Jan}},
  issn         = {{1600-0609}},
  language     = {{eng}},
  month        = {{07}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{European Journal of Haematology}},
  title        = {{Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A}},
  url          = {{http://dx.doi.org/10.1111/ejh.70269}},
  doi          = {{10.1111/ejh.70269}},
  year         = {{2026}},
}